DNTH icon

Dianthus Therapeutics
DNTH

Overview Fund Activity

76 hedge funds and large institutions have $782M invested in Dianthus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
76
Holders Change
+37
Holders Change %
+94.87%
% of All Funds
1.1%
Holding in Top 10
6
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+500%
% of All Funds
0.09%
New
39
Increased
24
Reduced
8
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$89.8M
2
RCM
2
RA Capital Management
Massachusetts
$70M
3
Fidelity Investments
3
Fidelity Investments
Massachusetts
$125M
4
APM
4
Avidity Partners Management
Texas
$81.5M
5
VA
5
VR Adviser
New York
$62.8M

Top Sellers

1
TCM
1
Tang Capital Management
California
$7.94M
2
5VM
2
5AM Venture Management
California
$37.3M
3
NCM
3
Nantahala Capital Management
Connecticut
$0
4
AVLSA
4
Atlas Venture Life Science Advisors
Massachusetts
$5.61M
5
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$120K
Name Holding Trade Value Shares
Change 		Shares
Change %
Macquarie Group
76
Macquarie Group
Australia
$55 +$55 +1,824 New
NCM
77
Nantahala Capital Management
Connecticut
– -$3.42M -328,433 Closed
ACM
78
ADAR1 Capital Management
Texas
– -$5K -481 Closed
1 2 3
4